ATE233814T1 - Humaner neutralisierender monoklonaler antikörper gegen den die immunschwäche beim menschen hervorringenden virus - Google Patents

Humaner neutralisierender monoklonaler antikörper gegen den die immunschwäche beim menschen hervorringenden virus

Info

Publication number
ATE233814T1
ATE233814T1 AT93923749T AT93923749T ATE233814T1 AT E233814 T1 ATE233814 T1 AT E233814T1 AT 93923749 T AT93923749 T AT 93923749T AT 93923749 T AT93923749 T AT 93923749T AT E233814 T1 ATE233814 T1 AT E233814T1
Authority
AT
Austria
Prior art keywords
human
virus
monoclonal antibody
antibody against
immune deficiency
Prior art date
Application number
AT93923749T
Other languages
English (en)
Inventor
Dennis R Burton
Carlos F Barbas
Richard A Lerner
Original Assignee
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scripps Research Inst filed Critical Scripps Research Inst
Application granted granted Critical
Publication of ATE233814T1 publication Critical patent/ATE233814T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/112—Retroviridae (F), e.g. leukemia viruses
    • C07K16/114—Lentivirus (G), e.g. human immunodeficiency virus [HIV], feline immunodeficiency virus [FIV] or simian immunodeficiency virus [SIV]
    • C07K16/1145—Env proteins, e.g. gp41, gp110/120, gp160, V3, principal neutralising domain [PND] or CD4-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AT93923749T 1992-09-30 1993-09-30 Humaner neutralisierender monoklonaler antikörper gegen den die immunschwäche beim menschen hervorringenden virus ATE233814T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95414892A 1992-09-30 1992-09-30
PCT/US1993/009328 WO1994007922A1 (en) 1992-09-30 1993-09-30 Human neutralizing monoclonal antibodies to human immunodeficiency virus

Publications (1)

Publication Number Publication Date
ATE233814T1 true ATE233814T1 (de) 2003-03-15

Family

ID=25495000

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93923749T ATE233814T1 (de) 1992-09-30 1993-09-30 Humaner neutralisierender monoklonaler antikörper gegen den die immunschwäche beim menschen hervorringenden virus

Country Status (10)

Country Link
EP (1) EP0675904B1 (de)
JP (1) JPH08502260A (de)
AT (1) ATE233814T1 (de)
AU (1) AU681360B2 (de)
CA (1) CA2145757A1 (de)
DE (1) DE69332744T2 (de)
ES (1) ES2194015T3 (de)
FI (1) FI951488L (de)
NO (1) NO951212L (de)
WO (1) WO1994007922A1 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT744958E (pt) 1994-01-31 2003-11-28 Univ Boston Bancos de anticorpos policlonais
US6193982B1 (en) 1995-04-27 2001-02-27 The United States Of America As Represented By The Department Of Health & Human Services Anti-cyanovirin antibody with an internal image of gp120, a method of use thereof, and a method of using a cyanovirin to induce an immune response to gp120
US6987096B1 (en) 1995-04-27 2006-01-17 The United States Of America As Represented By The Department Of Health And Human Services Antiviral proteins and peptides, DNA coding sequences therefor, and uses thereof
US5843882A (en) 1995-04-27 1998-12-01 The United States Of America As Represented By The Department Of Health And Human Services Antiviral proteins and peptides
US7048935B2 (en) 1995-04-27 2006-05-23 The United States Of America As Represented By The Department Of Health And Human Services Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use
US6428790B1 (en) 1995-04-27 2002-08-06 The United States Of America As Represented By The Secretary Department Of Health And Human Services Cyanovirin conjugates and matrix-anchored cyanovirin and related compositions and methods of use
US6780847B2 (en) 1995-04-27 2004-08-24 The United States Of America As Represented By The Department Of Health And Human Services Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins
US6255455B1 (en) 1996-10-11 2001-07-03 The Trustees Of The University Of Pennsylvania Rh(D)-binding proteins and magnetically activated cell sorting method for production thereof
DE19809785C2 (de) * 1998-03-08 2000-02-10 Wolfgang Bergter Radioimmunpharmakon zur Behandlung der HIV-1-Infektion
JP2002519334A (ja) * 1998-06-29 2002-07-02 ベルクター，ヴォルフガンク αエミッタとβエミッタとを主成分とする抗ウイルスおよび抗レトロウイルス放射免疫薬剤
EP1980617A1 (de) 1998-12-31 2008-10-15 Novartis Vaccines and Diagnostics, Inc. Verbesserte Expression von HIV-Polypeptiden und Herstellung virusähnlicher Partikel
WO2000039304A2 (en) 1998-12-31 2000-07-06 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
GB9908533D0 (en) 1999-04-14 1999-06-09 Novartis Ag Organic compounds
CA2798625C (en) 2000-04-17 2017-01-24 Dyax Corp. Novel methods of constructing libraries of genetic packages that collectively display the members of a diverse family of peptides, polypeptides or proteins
US8288322B2 (en) * 2000-04-17 2012-10-16 Dyax Corp. Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
PT1360288E (pt) 2000-12-18 2011-03-07 Dyax Corp Bibliotecas orientadas de pacotes genéticos
CA2441287C (en) 2001-03-22 2014-06-10 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Glycosylation-resistant cyanovirins and related conjugates, compositions, nucleic acids, vectors, host cells, methods of production and methods of using nonglycosylated cyanovirins
CA2452015C (en) 2001-07-05 2012-07-03 Chiron Corporation Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
US20030170614A1 (en) 2001-08-31 2003-09-11 Megede Jan Zur Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
CA2463931A1 (en) 2001-10-16 2003-04-24 The Government Of The United States Of America, Represented By The Secre Tary, Department Of Health And Human Services Broadly cross-reactive neutralizing antibodies against human immunodeficiency virus selected by env-cd4-co-receptor complexes
CA2485120C (en) 2002-05-06 2013-02-19 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Identification of novel broadly cross-reactive hiv-1 neutralizing human monoclonal antibodies
US7803913B2 (en) 2002-05-06 2010-09-28 The United States Of America As Represented By The Department Of Health And Human Services Identification of novel broadly cross-reactive neutralizing human monoclonal antibodies using sequential antigen panning of phage display libraries
US20040067532A1 (en) 2002-08-12 2004-04-08 Genetastix Corporation High throughput generation and affinity maturation of humanized antibody
US20070292390A1 (en) * 2004-10-29 2007-12-20 Dimitrov Dimiter S Broadly Cross-Reactive Hiv-1 Neutralizing Human Monoclonal Antibodies
US12529164B2 (en) 2007-09-14 2026-01-20 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
US8877688B2 (en) 2007-09-14 2014-11-04 Adimab, Llc Rationally designed, synthetic antibody libraries and uses therefor
EP3124497B1 (de) 2007-09-14 2020-04-15 Adimab, LLC Synthetische antikörperbibliotheken mit rationalem design und verwendungen davon
WO2009114815A1 (en) 2008-03-13 2009-09-17 Dyax Corp Libraries of genetic packages comprising novel hc cdr3 designs
WO2009132287A2 (en) 2008-04-24 2009-10-29 Dyax Corp. Libraries of genetic packages comprising novel hc cdr1, cdr2, and cdr3 and novel lc cdr1, cdr2, and cdr3 designs
KR102024922B1 (ko) 2010-07-16 2019-09-25 아디맵 엘엘씨 항체 라이브러리
EP2492279A1 (de) 2011-02-25 2012-08-29 Laboratorios Del. Dr. Esteve, S.A. Schnelles immunogenes Auswahlverfahren mittels Lentivirenanzeige
EP2698377A1 (de) 2012-08-17 2014-02-19 Laboratorios Del. Dr. Esteve, S.A. Verbessertes schnelles Immunogene Auswahlverfahren für HIV gp120 Varianten
CA3077340A1 (en) * 2017-11-17 2019-05-23 Grifols Diagnostic Solutions Inc. Novel mammalian expressed human immunodeficiency virus envelope protein antigens
CN118440202A (zh) 2019-12-27 2024-08-06 凯奥目生物科学株式会社 抗cdcp1抗体
CN116963779A (zh) 2020-09-02 2023-10-27 国立大学法人东京大学 癌症免疫微环境的调节物质及其预防、诊断或治疗
CN112521492B (zh) * 2020-12-18 2022-05-20 杭州贤至生物科技有限公司 乙肝表面抗原单克隆抗体的制备
US20250375498A1 (en) 2022-07-28 2025-12-11 The University Of Tokyo Neurotrimin function inhibitor

Also Published As

Publication number Publication date
ES2194015T3 (es) 2003-11-16
NO951212D0 (no) 1995-03-29
EP0675904B1 (de) 2003-03-05
CA2145757A1 (en) 1994-04-14
NO951212L (no) 1995-05-29
FI951488A7 (fi) 1995-05-23
JPH08502260A (ja) 1996-03-12
EP0675904A4 (de) 1996-08-21
FI951488L (fi) 1995-05-23
EP0675904A1 (de) 1995-10-11
AU5350194A (en) 1994-04-26
WO1994007922A1 (en) 1994-04-14
AU681360B2 (en) 1997-08-28
FI951488A0 (fi) 1995-03-29
DE69332744T2 (de) 2004-01-15
DE69332744D1 (de) 2003-04-10

Similar Documents

Publication Publication Date Title
DE69332744D1 (de) Humaner neutralisierender monoklonaler antikörper gegen den die immunschwäche beim menschen hervorringenden virus
ATE405679T1 (de) Synthetische humane neutralisierende monoklonale antikörper gegen hiv
NO970221L (no) Humane nöytraliserende monoklonale antistoffer mot humant immunsviktvirus
DE69942671D1 (de) Humanisierte antikoerper gegen gamma-interferon
EP0671927A4 (de) Menschliche, neutralisierende, monoklonale antikörper gegen das respiratorische synzytialviru.
HUP9802212A2 (hu) Humán terápiában alkalmazható rekombináns anti-CD4-ellenanyagok
DE69429095D1 (de) Humanisierte antikoerper
CO4480111A1 (es) Anticuerpos monoclonales de mono especificos para humanos b7. y/o b7.2, formas primatizadas de los mismos, composicio- nes farmaceuticas que los contienen, y uso de los mismos co- mo inmunosupresantes
ATE454163T1 (de) Bakterielle impfstoffe, enthaltend auxotrophe attenuierte listerienstämme, welche heterologe antigene exprimieren
MXPA03002480A (es) Inmunogeno que comprende ligando enlazado a proteinas de envoltura de vih.
CA2093667A1 (en) Mouse monoclonal antibodies and uses thereof
TW200517121A (en) Immunogen
MX9301858A (es) Anticuerpos monoclonales neutralizantes de hiv-humano recombinante para prevencion y tratamiento de infeccion hiv.
ITRM920457A0 (it) Anticorpi monoclonali che riconoscono un epitopo della p-glicoproteinaumana.
ES2114064T3 (es) Inmunoanalisis para la deteccion de colageno o fragmentos de colageno.
WO2004009785A3 (en) IgG Fc/HIV-gp120/C3d FUSION PROTEIN
CA2106719A1 (en) Reshaped monoclonal antibodies against an immunoglobulin isotype
DE69327529D1 (de) Immunologisch mit HLA homologe HIV Protein Epitope
MXPA01010437A (es) Complejo epitope fab del anticuerpo monoclonal 2f5 de neutralizacion cruzada de hiv-1.
SE9201281D0 (sv) New human monoclonal antibodies, and a method for preparation thereof
WO1991010735A3 (fr) Recepteur humain de la tsh. sequence codant pour ce recepteur
AU4959193A (en) High affinity, strongly neutralizing monoclonal antibodies against the CD-4 binding site of GP120 of human immunodeficiency virus
DE68925365D1 (de) PEPTIDE, DIE EPITOPE AUF R-IFN-BETA REPRÄSENTIEREN, ANTIKöRPER DAGEGEN, UND IHRE ANWENDUNG
FI934963A7 (fi) CTAA 81AV78, monoklonaalisen 81AV78-humaanivasta-aineen tunnistama ant igeeni
EP0537168A4 (en) Ctaa 28a32, the antigen recognized by mca 28a32

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties